{"entity":{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","aka":[],"tldr":"Oncolytics Biotech is a United States-based biotechnology company running 3 late-stage cancer trials of Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer and anal cancer.","summary":"Oncolytics Biotech, based in San Diego, the United States, is a biotechnology company. Oncolytics Biotech develops immunotherapies for gastrointestinal and other cancers, centred on pelareorep, an investigational double-stranded RNA immunotherapeutic agent. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer, anal cancer and pancreatic ductal adenocarcinoma. The largest, NCT07280377 (A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab), plans to enrol 122 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Oncolytics_Biotech","links":[{"label":"Official website","url":"https://www.oncolyticsbiotech.com"},{"label":"ClinicalTrials.gov: trials led by Oncolytics Biotech","url":"https://clinicaltrials.gov/search?lead=Oncolytics%20Biotech"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","breast-hr-positive","anal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07446322","nct07280377"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego","country":"US","companyType":"biotech","website":"https://www.oncolyticsbiotech.com","stage":"public","investors":[],"funding":[]},"route":"/companies/oncolytics-biotech/","neighbours":{"cancer":[{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"trial":[{"id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","route":"/trials/nct07280377/"},{"id":"nct07446322","kind":"trial","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","route":"/trials/nct07446322/"}]}}